Norgine expands its partnership with Noventure to commercialise GELSECTAN® in France

Back to media releases
Next media release
05 March 2019

CORPORATE MEDIA RELEASE

NORGINE EXPANDS ITS PARTNERSHIP WITH NOVENTURE TO COMMERCIALISE GELSECTAN® IN FRANCE

 

AMSTERDAM, The Netherlands. 5th March 2019, 09:00 BST / 10:00 CET. Norgine B.V. today announced that it has expanded its partnership with Noventure S.L. by entering into an exclusive distribution agreement for GELSECTAN® in France. This deal expands on Norgine’s existing collaboration with Noventure S.L. under which Norgine distributes GELSECTAN® in Portugal, Spain, Andorra and the Italian Republic (incl. Vatican City and San Marino).

GELSECTAN® is a Class IIa CE marked medical device used as a treatment for irritable bowel syndrome (IBS) with diarrhoea (IBS-D). IBS is a chronic bowel problem, characterized by abdominal pain, bloating, and changes in bowel habit[1]. Diarrhoea is one of the symptoms often associated with irritable bowel syndrome. GELSECTAN® is available in capsules for oral use.

Peter Martin, Chief Operating Officer at Norgine said: “We are delighted to expand our collaboration with Noventure. GELSECTAN® has already been successfully launched by Norgine in Spain and Portugal and has received very favourable feedback from patients who have taken it who suffer from irritable bowel syndrome with diarrhoea.”

Jose Luis Fumanal, VP Sales & Marketing at Noventure said: “Robust pre-clinical and clinical evidence, along with increasing real-life experience in a number of European markets, has positioned GELSECTAN® as one of the preferred treatment options for both IBS-D sufferers and physicians. Given our fruitful collaboration in Spain, Portugal and Italy, we are convinced that Norgine is the right partner to market GELSECTAN® in France.”

Norgine anticipates launching GELSECTAN® in France in the 3rd quarter of 2019.  

 

Notes to Editors:

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply. Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands. 

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

About Noventure

Noventure is an innovation-based enterprise, headquartered in Barcelona, specialized in licensing medical devices to partner companies. Noventure’s products are natural polymers based on a proprietary barrier technology that reinforces the epithelia, thereby restoring its functionality. Noventure’s areas of interest are gastroenterology, paediatrics, urogynaecology, allergy and dermatology

Noventure aims to build exclusive, long-term partnerships based on a shared understanding of the medical needs and the marketing opportunities in each country. Noventure has a growing network of partners and distributors with 150 ongoing brand and country agreements, 75 of them with products already on the market.  For more information visit us at www.noventure.com.

 

Media Contacts:

For Norgine:

Eleni Fistikaki +44 (0)1895826227 or +44 (0)7825 389477

Clara Bentham +44 (0)1895 826654 or +44 (0)7734 367883

contact@norgine.com

Follow us on twitter @norgine

For Noventure:

Nick Russell +34 93 600 3700

comunicacion@ferrer.com

[1]Longstreth G F et al. Functional bowel disorders. Gastroenterology. 2006; 130 (5): 1480 – 1491.